Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Whitehawk Therapeutics, Inc. WHWK
$3.09
▼ -4.04%
($-0.13)
⬇️ Below Yest. Low
Open
$3.15
Prev Close
$3.22
Day Range
$2.97 – $3.19
52W Range
$1.97 – $5.50
Market Cap
$184.71M
Beta
0.97
EPS (TTM)
$-3.03
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-06-26 |
| Shares Out. | 57,010,000 |
| Website | whitehawktx.com ↗ |
| Phone | 13026587581 |
| Employees | 23 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$16.6M |
| Free Cash Flow | -$69.3M |
| Total Assets | $194.0M |
| Total Liabilities | $11.1M |
| Equity | $182.9M |
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
Whitehawk Therapeutics, Inc. is a publicly traded company under the ticker symbol WHWK on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-11-01)